Kristie L. Kahl

After almost 5 years of follow-up, results strongly support upfront daratumumab with lenalidomide and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Treatment with the off-the-shelf, full-size BCMA X CD3 bi-specific antibody appeared well tolerated with promising efficacy among patients with relapsed/refractory multiple myeloma.

For men with asymptomatic or mildly symptomatic mCRPC, using bone-protecting agents during treatment with radium-223 plus enzalutamide controlled the risk for fractures.

Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.

The CAR T-cell product idecabtagene vicleucel in patients with heavily pretreated multiple myeloma continued to show benefit of therapy at a median follow-up of 24.8 months.

Awaited outcomes of the phase 3 OUTBACK trial presented at the 2021 ASCO Annual Meeting do not indicate benefit of adjuvant chemotherapy for patients with cervical cancer.

A review of safety and efficacy data demonstrated by the IMpower133 clinical trial of atezolizumab plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer.

Sameh Gaballa, MD, focuses on unmet needs and the future of the treatment landscape for follicular lymphoma.

A key opinion leader reviews the role of PI3K kinase inhibitors in the third-line or later settings for the treatment of follicular lymphoma.

A discussion regarding typical response rates to frontline therapy for extensive-stage small cell lung cancer and considerations for incorporating an immunotherapy agent into first-line treatment.

An overview of current gaps in treatment for patients with extensive-stage, or metastatic small cell lung cancer.

Dr Benjamin Levy describes common treatment approaches for patients with limited-stage small cell lung cancer and extensive-stage small cell lung cancer.

A leader in diagnosis and management of CRC reviews the role of MRD testing in early stage CRC.

Benjamin Levy, MD, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, comments on risk factors and the prognosis for patients diagnosed with small cell lung cancer.

In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Reshma L. Mahtani, DO, about genomic testing to optimize treatment outcomes in HR-positive breast cancer.

Practical implications of the IMpower133 study for providers and patients.

Dr Mark Socinski reviews the IMpower133 trial of first-line chemotherapy plus atezolizumab in extensive-stage small cell lung cancer.

Sameh Gaballa, MD, considers therapeutic options in the third-line setting and beyond for patients who relapse.

Sameh Gaballa, MD, discusses molecular testing in the third-line setting and beyond, as well as the mechanism of action of tazemetostat in the treatment of relapsed/refractory follicular lymphoma.

In this special edition of the “Oncology Peer Review On-The-Go” podcast, CancerNetwork spoke with Vijayakrishna (VK) Gadi, MD, PhD about the current role of genomic testing in HR-positive breast cancer.

A review of current options for management of SCLC and the challenges of treating this population.

An expert in follicular lymphoma highlights factors to consider when choosing therapy for first relapse and how this impacts later line treatment, as well as molecular testing and MRD.

Sameh Gaballa, MD, discusses patients who relapse after frontline treatment as well as prognostic and predictive factors for relapse.

Mark Socinski, MD, of AdventHealth Cancer Institute discusses his approach to treating small cell lung cancer and reacts to advances in the treatment of extensive-stage disease.

An overview of the prevalence and prognosis of small cell lung cancer.

An overview of unmet needs surrounding current treatment patterns for early-stage HR+ breast cancer.

Thoughts regarding how the addition of the Breast Cancer Index to the NCCN guidelines for HR+ breast cancer may likely impact extended adjuvant therapy and patient outcomes.

Dr Reshma L. Mahtani, of Sylvester Comprehensive Cancer Center, describes when and for whom she recommends genomic testing for HR+ breast cancer.

A review of recent updates to genomic testing guidelines by the National Comprehensive Cancer Network and important takeaways that impact treatment decisions for HR+ breast cancer in the extended adjuvant setting.